These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
    Author: Kuroda H, Jomen W, Yoshida M, Usami M, Yamada M, Abe T, Sakurai T, Fujii S, Maeda M, Matsuno T, Sato M, Kanari Y, Kato J.
    Journal: Gan To Kagaku Ryoho; 2014 Sep; 41(9):1179-82. PubMed ID: 25248908.
    Abstract:
    BiRd combination therapy, which comprises clarithromycin (CAM: Biaxin®), lenalidomide (LEN: Revlimid®), and dexamethasone ( DEX), is a highly effective treatment for newly diagnosed symptomatic myeloma. However, its efficacy against recurrent myeloma refractory to combination therapy with LEN and DEX(Rd therapy) remains unclear. Here, we report on BiRd therapy administered to three patients with IgA myeloma exacerbated during Rd therapy and for whom transplantation was not indicated, by adding CAM to the Rd regimen. Because the IgA levels increased again after Rd therapy in all patients, treatment was switched to BiRd therapy. In all cases, the IgA levels decreased after switching to BiRd therapy, with no exacerbation or hematological or non-hematological toxicity observed. Thus, BiRd therapy may represent a therapeutic option for symptomatic myeloma resistant to Rd therapy.
    [Abstract] [Full Text] [Related] [New Search]